Search results for "Harm"

showing 10 items of 13866 documents

Oxidative stress, autophagy, epigenetic changes and regulation by miRNAs as potential therapeutic targets in osteoarthritis

2015

Aging is a natural process characterized by the declining ability of the different organs and tissues to respond to stress, increasing homeostatic imbalance and risk of disease. Osteoarthritis (OA) is a multifactorial disease in which cartilage degradation is a central feature. Aging is the main risk factor for OA. In OA cartilage, a decrease in the number of chondrocytes and in their ability to regenerate the extracellular matrix and adequately respond to stress has been described. OA chondrocytes show a senescence secretory phenotype (SSP) consisting on the overproduction of cytokines (interleukins 1 and 6), growth factors (e.g., epidermal growth factor) and matrix metalloproteinases (MMP…

0301 basic medicineSenescenceMAPK/ERK pathwayAgingProgrammed cell deathDNA damageBiologymedicine.disease_causeBiochemistryChondrocyteEpigenesis Genetic03 medical and health sciencesChondrocytesOsteoarthritisAutophagymedicineAnimalsHumansMolecular Targeted TherapyEpigeneticsCellular SenescencePharmacologyAutophagyDNA MethylationCell biologyMicroRNAsOxidative Stress030104 developmental biologymedicine.anatomical_structureImmunologyReactive Oxygen SpeciesOxidative stressDNA DamageBiochemical Pharmacology
researchProduct

Therapeutic potential of polyphenols in cardiovascular diseases: Regulation of mTOR signaling pathway

2020

Cardiovascular diseases comprise of non-communicable disorders that involve the heart and/or blood vessels and have become the leading cause of death worldwide with increased prevalence by age. mTOR is a serine/threonine-specific protein kinase which plays a central role in many physiological processes including cardiovascular diseases, and also integrates various proliferative signals, nutrient and energy abundance and stressful situations. mTOR also acts as central regulator during chronic stress, mitochondrial dysfunction and deregulated autophagy which are associated with senescence. Under oxidative stress, mTOR has been reported to exert protective effects regulating apoptosis and auto…

0301 basic medicineSenescenceRegulatorDiseasemedicine.disease_causeNatural product03 medical and health sciences0302 clinical medicineAnimalsHumansMedicineChronic stressProtein kinase API3K/AKT/mTOR pathwayPharmacologybusiness.industryTOR Serine-Threonine KinasesAutophagyPolyphenols030104 developmental biologyCardiovascular Diseases030220 oncology & carcinogenesismTORCancer researchTranscription factorbusinessOxidative stressSignal TransductionPharmacological Research
researchProduct

An RNA toolbox for cancer immunotherapy.

2018

Cancer immunotherapy has revolutionized oncology practice. However, current protein and cell therapy tools used in cancer immunotherapy are far from perfect, and there is room for improvement regarding their efficacy and safety. RNA-based structures have diverse functions, ranging from gene expression and gene regulation to pro-inflammatory effects and the ability to specifically bind different molecules. These functions make them versatile tools that may advance cancer vaccines and immunomodulation, surpassing existing approaches. These technologies should not be considered as competitors of current immunotherapies but as partners in synergistic combinations and as a clear opportunity to r…

0301 basic medicineSequence analysismedicine.medical_treatmentComputational biologyBiologyCancer VaccinesCell therapyImmunomodulation03 medical and health sciencesImmune systemCancer immunotherapyNeoplasmsDrug DiscoveryGene expressionmedicineAnimalsHumansPharmacologyRegulation of gene expressionRNACancerGeneral Medicinemedicine.disease030104 developmental biologyRNARNA InterferenceImmunotherapyNature reviews. Drug discovery
researchProduct

Anti-PCSK9 treatment: is ultra-low low-density lipoprotein cholesterol always good?

2018

Anti-PCSK9 (proprotein convertase subtilisin kexin 9) monoclonal antibodies (Mab) are novel, potent lipid-lowering drugs. They demonstrated to improve the lipid profile in high cardiovascular risk patients. Anti-PCSK9 Mab inhibit the targeted low-density lipoprotein (LDL)-receptor degradation induced by PCSK9 protein and are able to reduce LDL cholesterol (LDL-C) levels on top of conventional lipid-lowering therapy. Though these drugs proved to be very safe in the short-term, little is known about the possible long-term effects, due to the short period of their marketing. The genetic low cholesterol syndromes (LCS) represent the natural models of the lipid-lowering anti-PCSK9 therapy, and a…

0301 basic medicineSerine Proteinase InhibitorsTime FactorsPhysiologymedicine.drug_class030204 cardiovascular system & hematologyPharmacologyMonoclonal antibodyRisk Assessment03 medical and health sciencesPCSK9 Genechemistry.chemical_compound0302 clinical medicineRisk FactorsPhysiology (medical)Diabetes mellitusmedicineAnimalsHumansDyslipidemiasmedicine.diagnostic_testbusiness.industryCholesterolPCSK9Anticholesteremic AgentsPCSK9 InhibitorsAntibodies MonoclonalCholesterol LDLmedicine.diseaseFatty LiverHypocholesterolemia030104 developmental biologyTreatment OutcomechemistryDiabetes Mellitus Type 2lipids (amino acids peptides and proteins)Proprotein Convertase 9Cardiology and Cardiovascular MedicineLipid profilebusinessCognition DisordersBiomarkersLipoproteinCardiovascular research
researchProduct

Antimicrobial and Antibiofilm Activity of a Recombinant Fragment of β-Thymosin of Sea Urchin Paracentrotus lividus

2018

With the aim to obtain new antimicrobials against important pathogens such as Staphylococcus aureus and Pseudomonas aeruginosa, we focused on antimicrobial peptides (AMPs) from Echinoderms. An example of such peptides is Paracentrin 1 (SP1), a chemically synthesised peptide fragment of a sea urchin thymosin. In the present paper, we report on the biological activity of a Paracentrin 1 derivative obtained by recombination. The recombinant paracentrin RP1, in comparison to the synthetic SP1, is 22 amino acids longer and it was considerably more active against the planktonic forms of S. aureus ATCC 25923 and P. aeruginosa ATCC 15442 at concentrations of 50 &micro

0301 basic medicineSettore BIO/05 - ZoologiaPharmaceutical Science<i>Staphylococcus aureus</i>Peptide<i>Paracentrotus lividus</i>Settore BIO/19 - Microbiologia Generalemedicine.disease_causebiofilmDrug DiscoveryPharmacology Toxicology and Pharmaceutics (miscellaneous)lcsh:QH301-705.5chemistry.chemical_classificationbiologyMicrobial Sensitivity TestChemistrymolecular dynamicBiological activityRecombinant ProteinAntimicrobialRecombinant ProteinsAnti-Bacterial AgentsBiochemistrySettore CHIM/03 - Chimica Generale E InorganicaStaphylococcus aureusPeptidePseudomonas aeruginosaStaphylococcus aureuParacentrotusAntibacterial activityAMP (antimicrobial peptides)Staphylococcus aureusSea UrchinAntimicrobial peptidesMicrobial Sensitivity TestsParacentrotus lividusArticle03 medical and health sciencesAnti-Bacterial AgentmedicineAnimalsAMP (antimicrobial peptides); Paracentrotus lividus; Pseudomonas aeruginosa; Staphylococcus aureus; biofilm; molecular dynamics; thymosinAnimalBiofilmthymosinbiology.organism_classificationmolecular dynamics<i>Pseudomonas aeruginosa</i>030104 developmental biologylcsh:Biology (General)Paracentrotus lividusBiofilmsSea UrchinsParacentrotuPeptidesParacentrotus lividuMarine Drugs
researchProduct

Immunomodulatory effects of stem cells: Therapeutic option for neurodegenerative disorders.

2017

Stem cells have the capability of self-renewal and can differentiate into different cell types that might be used in regenerative medicine. Neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS) currently lack effective treatments. Although stem cell therapy is still on the way from bench to bedside, we consider that it might provide new hope for patients suffering with neurodegenerative diseases. In this article, we will give an overview of recent studies on the potential therapeutic use of mesenchymal stem cells (MSCs), neural stem cells (NSCs), embryonic stem cells (ESCs), induced pluripotent…

0301 basic medicineSettore BIO/17 - IstologiaPathologymedicine.medical_specialtymedicine.medical_treatmentRegenerative medicineModels Biological03 medical and health sciencesmedicineAnimalsHumansImmunologic FactorsInduced pluripotent stem cellPharmacologyStem cell therapybusiness.industryMultiple sclerosisStem CellsMesenchymal stem cellNeurodegenerative DiseasesGeneral MedicineStem-cell therapyNeurodegenerative disordermedicine.diseaseEmbryonic stem cellNeural stem cell030104 developmental biologyRegenerative medicineStem cellbusinessNeuroscienceStem Cell TransplantationBiomedicinepharmacotherapy = Biomedecinepharmacotherapie
researchProduct

Gut microbiota and cancer: How gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy

2019

Gut microbiota is involved in gastrointestinal carcinogenesis. Also, it modulates the activity, efficacy and toxicity of several chemotherapy agents, such as gemcitabine, cyclophosphamide, irinotecan, cisplatin and 5-Fluorouracil, and target therapy, such as tyrosine kinase inhibitors. More recently, accumulating data suggest that the composition of gut microbiota may also affect efficacy and toxicity of cancer immunotherapy. Therefore, the manipulation of gut microbiota through antibiotics, probiotics, prebiotics or fecal transplantation has been investigating with the aim to improve efficacy and mitigate toxicity of anticancer drugs.

0301 basic medicineSettore MED/06 - Oncologia Medicamedicine.drug_class5-Fluorouracilmedicine.medical_treatmentAntibioticsAntineoplastic AgentsImmune checkpoint inhibitorGut floraPharmacologyIrinotecandigestive systemImmune checkpoint inhibitors03 medical and health sciences0302 clinical medicineCancer immunotherapyNeoplasmsmedicineAnimalsHumansCyclophosphamide5-Fluorouracil; Cisplatin; Cyclophosphamide; Gemcitabine; Immune checkpoint inhibitors; Irinotecan; Microbiota; Tyrosine kinase inhibitorsTyrosine kinase inhibitorsChemotherapybiologybusiness.industryMicrobiotaCancerHematologyFecal Microbiota Transplantationbiology.organism_classificationmedicine.diseaseGemcitabineGemcitabineGastrointestinal MicrobiomeIrinotecan030104 developmental biologyOncology030220 oncology & carcinogenesisToxicityImmunotherapyCisplatinbusinessmedicine.drugCritical Reviews in Oncology/Hematology
researchProduct

Clinical Characteristics and Outcomes of Patients with COVID-19 Infection: The Results of the SARS-RAS Study of the Italian Society of Hypertension

2021

: The COVID-19 infection has rapidly spread around the world and a second wave is sweeping in many countries. Different clinical and epidemiological aspects characterize the disease and their understanding is necessary to better face the management of the pandemic in progress. The Italian society of arterial hypertension with the SARS-RAS study has contributed significantly to the knowledge of the interaction between inhibition of the renin-angiotensin system and COVID-19 infection. Furthermore, the study results help to understand some of the main aspects related to mortality and morbidity deriving from the infection through a multicentre analysis throughout the national territory.

0301 basic medicineSettore MED/09 - Medicina InternaCross-sectional studyDiseaseComorbiditySeverity of Illness IndexComorbiditiesRenin-Angiotensin System0302 clinical medicineRisk FactorsSex-differences.EpidemiologyPandemicFrailtySars-Cov2Treatment OutcomeItalyAnti-hypertensive therapy; comorbidities; frailty; Sars-Cov2; sex-differencesHypertensionComorbiditiePosition PaperRisk assessmentCardiology and Cardiovascular Medicinemedicine.medical_specialtySex-differenceRisk Assessment03 medical and health sciencesPharmacotherapySex FactorsSeverity of illnessmedicineAnti-hypertensive therapy Sars-Cov2 Frailty Comorbidities Sex-differencesInternal MedicineHumansArterial PressureAnti-hypertensive therapy Comorbidities Frailty Sars-Cov2 Sex-differencesIntensive care medicineAnti-hypertensive therapyAntihypertensive AgentsAnti-hypertensive therapy; Comorbidities; Frailty; Sars-Cov2; Sex-differences; Antihypertensive Agents; Arterial Pressure; COVID-19; Comorbidity; Cross-Sectional Studies; Frailty; Humans; Hypertension; Italy; Renin-Angiotensin System; Risk Assessment; Risk Factors; Severity of Illness Index; Sex Factors; Treatment OutcomeSettore MED/14 - Nefrologiabusiness.industryCOVID-19medicine.diseaseComorbiditySex-differences030104 developmental biologyCross-Sectional Studiesbusiness030217 neurology & neurosurgery
researchProduct

Altilix® Supplement Containing Chlorogenic Acid and Luteolin Improved Hepatic and Cardiometabolic Parameters in Subjects with Metabolic Syndrome: A 6…

2019

The objective was to evaluate the effects of 6 months of supplementation with Altilix&reg

0301 basic medicineSettore MED/09 - Medicina Internacynaragenetic structuresPlacebo-controlled study030204 cardiovascular system & hematologySettore BIO/09 - FisiologiaGastroenterology0302 clinical medicineDiabetes mellitusimmune system diseasescardiovascular diseasehemic and lymphatic diseasesBrachial arteryLuteolinNutrition and Dieteticsdiabetes mellituFatty liverhemic and immune systemsDietary supplementsMetabolic syndromeCardiovascular diseasesLivertype 2diabetes mellitusChlorogenic Acidlcsh:Nutrition. Foods and food supplymedicine.medical_specialtyWaistlcsh:TX341-641chemical and pharmacologic phenomenaCynaraPlacebometabolic syndromedietary supplements03 medical and health sciencesDouble-Blind MethodInternal medicineDiabetes mellitusmedicine.arterymedicinebusiness.industrynon-alcoholic fatty liver diseasemedicine.diseasecardiovascular diseases030104 developmental biologydietary supplementSteatosisMetabolic syndromebusinessFood ScienceNon-alcoholic fatty liver disease
researchProduct

Antibodies Responses to SARS-CoV-2 in a Large Cohort of Vaccinated Subjects and Seropositive Patients

2021

COVID-19 is a current global threat, and the characterization of antibody response is vitally important to update vaccine development and strategies. In this study we assessed SARS-CoV-2 antibody concentrations in SARS-CoV-2 positive patients (N = 272) and subjects vaccinated with the BNT162b2 m-RNA COVID-19 vaccine (N = 1256). For each participant, socio-demographic data, COVID-19 vaccination records, serological analyses, and SARS-CoV-2 infection status were collected. IgG antibodies against S1/S2 antigens of SARS-CoV-2 were detected. Almost all vaccinated subjects (99.8%) showed a seropositivity to anti-SARS-COV-2 IgG and more than 80% of vaccinated subjects had IgG concentrations &gt

0301 basic medicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)virusesImmunologyArticleSerologyPersistence (computer science)03 medical and health sciences0302 clinical medicineAntigenDrug DiscoveryMedicinePharmacology (medical)030212 general & internal medicineskin and connective tissue diseasesPharmacologyantibody concentrations.biologybusiness.industryImmunogenicitySARS-CoV-2 infectionfungiRantibody concentrationsrespiratory tract diseasesVaccinationbody regions030104 developmental biologyInfectious DiseasesImmunizationImmunologybiology.proteinMedicineAntibodybusinessCOVID-19 vaccineVaccines
researchProduct